CAR-T THERAPY IS REVOLUTIONIZING CANCER TREATMENT. NEXT ON THE LIST: AUTOIMMUNE DISEASE
A woman who had been sick for many years with three autoimmune conditions has experienced a remarkable recovery after being treated with CAR-T therapy. This revolutionary cell-based therapy has been making waves in cancer science, but this case marks the first time it’s been successfully used in someone with these three life-threatening disorders.
CAR-T therapy takes a patient’s own cells and essentially turns them into targeted, disease-fighting machines. It’s been particularly promising for blood cancers – last year, early results from a clinical trial of a treatment based on this technology showed its impressive effects in patients with an aggressive type of leukemia.
First approved in the US in 2017, these therapies start with the extraction of a patient’s T cells, which are a subset of white blood cells and “the body’s primary killer of infected and other diseased cells,” explains the National Cancer Institute.
The harvested cells are genetically engineered to produce surface proteins called chimeric antigen receptors, the eponymous CARs. These work well for cancer treatment because they allow the modified cells to latch onto and kill cancerous cells via surface antigens that they express.
The CAR-T cells are expanded in the lab until there are hundreds of millions of them that are then infused back into the patient, with the whole process of producing and delivering this “living drug” taking about three to five weeks.
Autoimmune disorders: the next frontier?
Research into the use of CAR-T cells in cancer treatment is continuing apace, and they’ve proven a very promising approach in some patients who, for example, have not responded well to first-line chemotherapies. Progress in solid tumors has been slower, but some preliminary results have been cause for optimism.
But what about other diseases?
“We believe that using CAR-T therapy earlier for patients with severe autoimmune disease could help prevent complications from years of ineffective treatments,” said Fabian Müller of the University Hospital of Erlangen, Germany, in a statement. “If we can intervene sooner, we may be able to stop the disease process, avoid organ damage, and give patients their lives back.”
That’s exactly what Müller and colleagues had been investigating at their clinic when, in 2025, they met with a patient who had found no symptom relief from over a decade of different treatments for her autoimmune disorders.
The 47-year-old had been diagnosed with severe autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid antibody syndrome (APS). It’s a puzzling combination of conditions.
In AIHA, the immune system attacks and destroys the body’s own red blood cells, meaning the patient was undergoing daily blood transfusions to keep her levels high enough.
In ITP, serious bleeding can occur because the body attacks its own platelets. But with APS, you have almost the opposite problem with blood that clots too easily. The patient was taking blood thinners to combat this, but over the years she had had nine different treatments including immune suppression, steroids, and antibodies. None of these had worked, which is why CAR-T therapy seemed an option worth exploring.
Müller and his team concluded that dysregulated B cells were underlying the patient’s three different conditions. When they engineered the CAR-T cells, they primed them to recognize a protein called CD19 – which B cells express – with the hope that the re-infused CAR-Ts would go on to eliminate these problematic cells.
It worked.
“The treatment was extremely efficient in getting rid of all three autoimmune conditions at once. After being sick for more than a decade, the patient is now in treatment-free remission and able to return to an almost normal life. This therapy significantly improved her quality of life,” said Müller.
He believes the treatment essentially “reset” the patient’s immune system. By weeding out all the B cells at all different stages of maturation, the body was essentially able to start afresh. When it had had time to produce new B cells, they didn’t show signs of being disease-causing.
The patient was able to cease her blood transfusions, as her red blood cell levels returned to normal; her platelets stabilized; and her antiphospholipid antibody levels dropped, meaning she was no longer at risk of clots.
“The speed and depth of the response was remarkable,” said Müller.
Now, one year on, the patient has needed no ongoing treatment. Müller explained that while she does still have a lower-than-usual white cell count and signs of mild liver damage, these may be after-effects of all the prior treatments she had as opposed to the CAR-T therapy.
This is just one case; as the authors write in their paper, “more data from controlled clinical trials are needed for final conclusions.” But it does demonstrate that the principal of treating autoimmune conditions with CAR-T therapy is worth exploring further.
The study is published in the journal Med00078-4).
2026-04-10T17:04:12Z